|Bid||0.0000 x 800|
|Ask||0.0000 x 1000|
|Day's Range||0.3420 - 0.4180|
|52 Week Range||0.2700 - 1.2200|
|Beta (3Y Monthly)||2.47|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 7, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.95|
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 8.43%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Richland, Washington-based company said it had a loss of 2 cents per share. The isotope-based medical products maker posted revenue of $1.9 million in the period. In the final minutes of trading on ...
Record Revenue and Gross ProfitRevenue Increased 24% Year-Over-Year RICHLAND, Wash., Feb. 12, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and.
NEW YORK, NY / ACCESSWIRE / February 12, 2019 / IsoRay, Inc. (NYSEMKT: ISR ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on February 12, 2019 at 4:30 PM Eastern ...
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RICHLAND, WASH., Jan. 30, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options.
Dr. David T. Marshall, a professor of Radiation Oncology and Urology, and medical director of the Clinical Trials Office at the Hollings Cancer Center, performed the surgery on October 26, 2018. “No two patients are exactly alike.
Hunt has more than 25 years of finance and accounting experience excelling as a versatile leader with a successful track record in turnarounds, startups, mergers, divestitures, growth strategies, performance and operations management and analysis at a number of organizations, including Fortune 500 companies. “We are excited to have Jonathan back at IsoRay. Before joining IsoRay, Hunt was Chief Financial Officer at Vivid Learning Systems, where he had a central role in the company’s turnaround, that included growing revenues and implementing financial policy and process changes that ultimately resulted in the successful sale of the company.
NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -9.87%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Richland, Washington-based company said it had a loss of 2 cents. The isotope-based medical products maker posted revenue of $1.6 million in the period. In the final minutes of ...
On a per-share basis, the Richland, Washington-based company said it had a loss of 4 cents. The isotope-based medical products maker posted revenue of $1.6 million in the period. For the year, the company ...
IsoRay Inc’s (NYSEMKT:ISR): IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases inRead More...
The direct benefit for IsoRay Inc (NYSEMKT:ISR), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off isRead More...
On Friday, July 20, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: IsoRay Inc. (NYSE AMER: ISR), STAAR Surgical Co. (NASDAQ: STAA), Conformis Inc. (NASDAQ: CFMS), and Integra LifeSciences Holdings Corp. (NASDAQ: IART).
NEW YORK, NY / ACCESSWIRE / July 10, 2018 / Both Staffing 360 Solutions and IsoRay were two of the biggest winners in Monday’s trading session with gains of about 300% and 143% respectively. The company, which is an innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, said it plans to use the net proceeds from this offering for working capital and general corporate purposes with particular focus on marketing the brain applications and Build-Blu™ delivery system for real-time prostate brachytherapy.
Today, IsoRay Inc. (ISR) stock rallied ~160% and closed trading at $1.14, compared to its previous closing price of $0.44. IsoRay’s stock price was triggered by buoyed investor sentiment on the news of the FDA 510(k) clearance for the company’s GammaTile therapy for the treatment of recurrent brain tumors.